Please assess the completion status of the following clinical trial:

Trial Title: Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes \> 5 years~* One or more episodes of nocturnal severe hypoglycaemia during the preceding two years~* Treated with multiple dose insulin injection (\>2) or insulin pump. Both human insulin and insulin analogues are allowed~* Willingness to a once daily (OD) regimen concerning insulin degludec and insulin glargine~* Willingness to do self-monitoring of blood glucose (SMBG) and keep a diary~* Signed informed consent~Exclusion Criteria:~* History of primary and secondary adrenal insufficiency, growth hormone deficiency, or untreated myxoedema~* History of unstable angina or major cardiovascular events (myocardial infarction, coronary re-vascularisation, transient ischaemic attack, or stroke within the last three months)~* Heart failure, New York Heart Association (NYHA) class IV~* History of malignancy unless a disease-free period exceeding five years~* History of alcohol or drug abuse~* Treatment with glucose lowering agent(s) other than insulin~* Pregnant or lactating women~* Women of childbearing potential who are not using chemical (P-pills or gestagen depots) or mechanical (intra-uterine device) contraception~* Participation in another investigational drug study within the last 3 months~* Inability to understand the informed consent~* HbA1c \> 86 mmol/mol (10%)~* Shifting working hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (Type: ACTIVE_COMPARATOR): Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals.
- Insulin degludec (Type: EXPERIMENTAL): Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).